First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update
Reck, M., Ciuleanu, T.-E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., Alexandru, A., Sakai, H., Lingua, A., Reyes, F., Souquet, P.-J., De Marchi, P., Martin, C., Pérol, M., Scherpereel, A., Lu, S., Paz-Ares, L., Carbone, D.P., Memaj, A., Marimuthu, S., Zhang, X., Tran, P., John, T.
Published in ESMO open (01.10.2021)
Published in ESMO open (01.10.2021)
Get full text
Journal Article
Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer
Schoenfeld, A.J., Antonia, S.J., Awad, M.M., Felip, E., Gainor, J., Gettinger, S.N., Hodi, F.S., Johnson, M.L., Leighl, N.B., Lovly, C.M., Mok, T., Perol, M., Reck, M., Solomon, B., Soria, J.-C., Tan, D.S.W., Peters, S., Hellmann, M.D.
Published in Annals of oncology (01.12.2021)
Published in Annals of oncology (01.12.2021)
Get full text
Journal Article
Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer
Bonomi, P.D., Gandara, D., Hirsch, F.R., Kerr, K.M., Obasaju, C., Paz-Ares, L., Bellomo, C., Bradley, J.D., Bunn Jr, P.A., Culligan, M., Jett, J.R., Kim, E.S., Langer, C.J., Natale, R.B., Novello, S., Pérol, M., Ramalingam, S.S., Reck, M., Reynolds, C.H., Smit, E.F., Socinski, M.A., Spigel, D.R., Vansteenkiste, J.F., Wakelee, H., Thatcher, N.
Published in Annals of oncology (01.08.2018)
Published in Annals of oncology (01.08.2018)
Get full text
Journal Article
Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer
Rosell, R., Robinet, G., Szczesna, A., Ramlau, R., Constenla, M., Mennecier, B. C., Pfeifer, W., O'Byrne, K. J., Welte, T., Kolb, R., Pirker, R., Chemaissani, A., Perol, M., Ranson, M. R., Ellis, P. A., Pilz, K., Reck, M.
Published in Annals of oncology (01.02.2008)
Published in Annals of oncology (01.02.2008)
Get full text
Journal Article
EVIDENS: An observational study of nivolumab-treated patients in advanced non-small cell lung cancer (NSCLC) in a real-world setting: Initial results on 1394 patients
Dixmier, A., Debieuvre, D., Raspaud, C., Auliac, J.B., Benoit, N., Bombaron, P., Asselain, B., Dumont, A., Lamoureux, P., Goyard, N., Moro-Sibilot, D., Perol, M., Barlesi, F., Audigier Valette, C.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
Clinical outcomes in patients with advanced NSCLC treated with targeted therapies, with actionable mutations identified by InVisionFirst ctDNA assay
Remon, J., Mezquita, L., Ortiz-Cuaran, S., Jovelet, C., Lacroix, L., Morris, C., Green, E., Saintigny, P., Besse, B., Swalduz, A., Howarth, K., Rouleau, E., De Kievit, F., Baker-Neblett, K., Roitt, S., Plagnol, V., Perol, M., Planchard, D.
Published in Annals of oncology (01.09.2018)
Published in Annals of oncology (01.09.2018)
Get full text
Journal Article
Efficacy of immune checkpoint inhibitors in lung sarcomatoid carcinoma: Data from a French multicentric cohort
Domblides, C., Monnet, I., Mazieres, J., Barlesi, F., Gounant, V., Baldacci, S., Mennecier, B., Toffart, A.C., Audigier Valette, C., Doucet, L., Giroux-Leprieur, E., Guisier, F., Molinier, O., Perol, M., Pichon, E., Robinet, G., Templement Grangerat, D., Ruppert, A.-M., Wislez, M.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study
Gadgeel, S., Peters, S., Mok, T., Shaw, A.T., Kim, D.W., Ou, S.I., Pérol, M., Wrona, A., Novello, S., Rosell, R., Zeaiter, A., Liu, T., Nüesch, E., Balas, B., Camidge, D.R.
Published in Annals of oncology (01.11.2018)
Published in Annals of oncology (01.11.2018)
Get full text
Journal Article
Biomarker-driven access to crizotinib in ALK, MET or ROS1 positive (+) malignancies in adults and children: The French national AcSé program
Vassal, G, Cozic, N, Houot, R, Brugières, L, Aparicio, T, Blay, J-Y, Perol, M, Brice, P, Meriaux, E, Geoerger, B, El Bejjani, M R, Moalla, S, Bièche, I, Lantuejoul, S, Mahier Ait Oukhatar, C, Hoog Labouret, N, Moro-Sibilot, D
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
Clinical characteristic and survival outcomes of patients with advanced NSCLC according to KRAS mutational status in the French real-life ESME cohort
Thomas, Q.D., Quantin, X., Lemercier, P., Chouaid, C., Schneider, S., Filleron, T., Remon-Masip, J., Perol, M., Debieuvre, D., Audigier-Valette, C., Justeau, G., Loeb, A., Hiret, S., Clement-Duchene, C., Dansin, E., Stancu, A., Pichon, E., Bosquet, L., Girard, N., Du Rusquec, P.
Published in ESMO open (01.06.2024)
Published in ESMO open (01.06.2024)
Get full text
Journal Article
3062 Ceritinib following crizotinib in ALK-positive (+) advanced NSCLC patients (pts): Results from the French Temporary Authorization for Use (ATU) experience
Cadranel, J, Cortot, A, Lena, H, Mennecier, B, Do, P, Dansin, E, Mazieres, J, Chouaid, C, Perol, M, Barlesi, F
Published in European journal of cancer (1990) (01.09.2015)
Published in European journal of cancer (1990) (01.09.2015)
Get full text
Journal Article
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study
Mok, T., Camidge, D.R., Gadgeel, S.M., Rosell, R., Dziadziuszko, R., Kim, D.-W., Pérol, M., Ou, S.-H.I., Ahn, J.S., Shaw, A.T., Bordogna, W., Smoljanović, V., Hilton, M., Ruf, T., Noé, J., Peters, S.
Published in Annals of oncology (01.08.2020)
Published in Annals of oncology (01.08.2020)
Get full text
Journal Article
168P Real life practice of gefitinib in patients (pts) with non-small-cell lung cancer (NSCLC) depending on epidermal growth factor receptor (EGFR) mutation status: Results from the prospective EPIDAURE study
Cadranel, J., Brambilla, E., Morere, J.F., Rondeau, V., Fabre, E., Lemaire, B., Monnet, I., Licour, M., Perol, M.
Published in Journal of thoracic oncology (01.04.2016)
Published in Journal of thoracic oncology (01.04.2016)
Get full text
Journal Article
3105 Dose optimization of rociletinib for EGFR mutated NSCLC: Benefit/risk analysis from the TIGER-X trial
Soria, J.C, Goldman, J.W, Wakelee, H, Gadgeel, S, Camidge, D.R, Solomon, B, Yu, H, Oxnard, G.R, Ou, S.H, Papadimitrakopoulou, V, Perol, M, Reckamp, K, Varga, A, Dziadziuszko, R, Chouaid, C, Cortot, A, Do, P, Moro-Sibilot, D, Poudenx, M, Sequist, L.V
Published in European journal of cancer (1990) (01.09.2015)
Published in European journal of cancer (1990) (01.09.2015)
Get full text
Journal Article
3073 Exploratory analysis of frontline therapies in REVEL: A randomized phase III study of ramucirumab (RAM) plus docetaxel (DOC) versus DOC for the treatment of stage IV non-small-cell lung cancer (NSCLC) after disease progression on platinum-based therapy
Garon, E.B, Scagliotti, G.V, Gautschi, O, Reck, M, Thomas, M, Docampo, L.I, Kalofonos, H, Kim, J.H, Gans, S, Brustugun, O.T, Orlov, S.V, Ferry, D, Melemed, A, Carter, G.C, Zimmermann, A.H, Treat, J.A, Alexandris, E, Lee, P, Socinski, M.A, Perol, M
Published in European journal of cancer (1990) (01.09.2015)
Published in European journal of cancer (1990) (01.09.2015)
Get full text
Journal Article
Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data
Pérol, M., Felip, E., Dafni, U., Polito, L., Pal, N., Tsourti, Z., Ton, T.G.N., Merritt, D., Morris, S., Stahel, R., Peters, S.
Published in Annals of oncology (01.05.2022)
Published in Annals of oncology (01.05.2022)
Get full text
Journal Article
Anti‐PD1‐induced psoriasis: a study of 21 patients
Bonigen, J., Raynaud‐Donzel, C., Hureaux, J., Kramkimel, N., Blom, A., Jeudy, G., Breton, A.‐L., Hubiche, T., Bedane, C., Legoupil, D., Pham‐Ledard, A., Charles, J., Pérol, M., Gérard, E., Combemale, P., Bonnet, D., Sigal, M.‐L., Mahé, E.
Published in Journal of the European Academy of Dermatology and Venereology (01.05.2017)
Published in Journal of the European Academy of Dermatology and Venereology (01.05.2017)
Get full text
Journal Article
Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial
Moro-Sibilot, D., Cozic, N., Pérol, M., Mazières, J., Otto, J., Souquet, P.J., Bahleda, R., Wislez, M., Zalcman, G., Guibert, S.D., Barlési, F., Mennecier, B., Monnet, I., Sabatier, R., Bota, S., Dubos, C., Verriele, V., Haddad, V., Ferretti, G., Cortot, A., De Fraipont, F., Jimenez, M., Hoog-Labouret, N., Vassal, G.
Published in Annals of oncology (01.12.2019)
Published in Annals of oncology (01.12.2019)
Get full text
Journal Article